{"id":"W4281633340","doi":"10.1200/jco.2022.40.16_suppl.12100","title":"Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Eosinophilic Disorders and Syndromes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"National Institutes of Health","keywords":"Medicine; Benralizumab; Rash; Internal medicine; Clinical endpoint; Metastatic breast cancer; Interim analysis; Breast cancer; Oncology; Cancer; Clinical trial; Mepolizumab; Asthma; Eosinophil","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01218007,0.001903211,0.003442714,0.0004851392,0.000721394,0.001499977,0.0009591924,0.00158398,0.003428796],"category_scores_gemma":[0.007299999,0.0007388995,0.004038449,0.0004831352,0.0007046604,0.001125624,0.0006062245,0.002832701,0.0007869839],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007991993,"about_ca_system_score_gemma":0.002031449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000331188,"about_ca_topic_score_gemma":0.0007323812,"domain_scores_codex":[0.9961683,0.002235443,0.0002086278,0.0004610779,0.0004290695,0.0004974848],"domain_scores_gemma":[0.9941685,0.001773293,0.001589685,0.001136224,0.0005011594,0.0008311417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9176522,0.01372254,0.01973691,0.0004252656,0.007566289,0.0003103977,0.0001106776,0.004644075,0.009690836,0.0002141858,0.004166258,0.02176023],"study_design_scores_gemma":[0.387071,0.4888763,0.09370743,0.00005758496,0.008454596,0.0006816809,0.00009772066,0.007942642,0.007718513,0.0007684281,0.004518854,0.0001053334],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763979,0.002234446,0.004512796,0.0004279103,0.0003185526,0.006349253,0.006648232,0.0003143517,0.00279655],"genre_scores_gemma":[0.9726338,0.0004048492,0.006086049,0.0009833197,0.0001839947,0.008470159,0.009271112,0.0000975013,0.001869169],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01218007,"threshold_uncertainty_score":0.06441516,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139353397638302,"score_gpt":0.4737291701949902,"score_spread":0.35979383043116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}